WO2001035936A3 - Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases - Google Patents

Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases Download PDF

Info

Publication number
WO2001035936A3
WO2001035936A3 PCT/EP2000/010919 EP0010919W WO0135936A3 WO 2001035936 A3 WO2001035936 A3 WO 2001035936A3 EP 0010919 W EP0010919 W EP 0010919W WO 0135936 A3 WO0135936 A3 WO 0135936A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
chain
straight
branched alkyl
cyanamides
Prior art date
Application number
PCT/EP2000/010919
Other languages
French (fr)
Other versions
WO2001035936A2 (en
Inventor
William Taylor
Original Assignee
Bayer Ag
William Taylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, William Taylor filed Critical Bayer Ag
Priority to AU23543/01A priority Critical patent/AU2354301A/en
Publication of WO2001035936A2 publication Critical patent/WO2001035936A2/en
Publication of WO2001035936A3 publication Critical patent/WO2001035936A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of (quinolin-2-yl-methoxy)phenylacyl-sulphonamides and -cyanamides of formula (I), in which A, B, D, E, L and G are identical or different and represent hydrogen, hydroxyl, halogen, carboxyl, nitro, trifluoromethyl, trifluoromethoxy or a group of the formula -NR3R4, in which R?3 and R4¿ are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or aryl having 6 to 10 carbon atoms, represent straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 12 carbon atoms, represent aryl having 6 to 10 carbon atoms, R1 represents cycloalkyl having 3 to 8 carbon atoms; R2 represents hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms, represents an alkali metal, represents cycloalkyl having 3 to 8 carbon atoms; X represents a group of the formula -SO2-R5, in which R5 denotes trifluoromethyl or straight-chain or branched alkyl having up to 10 carbon atoms, or denotes aryl having 6 to 10 carbon atoms; or X represents cyano for the treatment and prevention of glomerular nephritis, lung cancer, multiple sclerosis, ocular inflammation, osteoporosis, reperfusion injury and tinnitus.
PCT/EP2000/010919 1999-11-15 2000-11-06 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases WO2001035936A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23543/01A AU2354301A (en) 1999-11-15 2000-11-06 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9926985A GB2356139A (en) 1999-11-15 1999-11-15 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases
GB9926985.4 1999-11-15

Publications (2)

Publication Number Publication Date
WO2001035936A2 WO2001035936A2 (en) 2001-05-25
WO2001035936A3 true WO2001035936A3 (en) 2002-03-28

Family

ID=10864542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010919 WO2001035936A2 (en) 1999-11-15 2000-11-06 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases

Country Status (3)

Country Link
AU (1) AU2354301A (en)
GB (1) GB2356139A (en)
WO (1) WO2001035936A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037097A1 (en) 2001-10-05 2004-10-20 Novartis Ag ACILSULFONAMID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399291A2 (en) * 1989-05-23 1990-11-28 Bayer Ag Substituted (Quinoline-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides , process for their preparation and their use in medicines
EP0480708A2 (en) * 1990-10-12 1992-04-15 Merck Frosst Canada Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
EP0582908A1 (en) * 1992-08-11 1994-02-16 Bayer Ag 2-Substituted guinolylmethoxy-phenylacetic acid derivatives, process for their preparation and their pharmaceutical use
EP0593976A1 (en) * 1992-10-19 1994-04-27 Bayer Ag Crystalline (R)-(-)-2-cycloheptyl-N-methylsulfonyl-4-(2-quinolinyl-methoxy)-phenyl-acetamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391747A (en) * 1989-05-23 1995-02-21 Bayer Aktiengesellschaft Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphon-amides and -cyanamides, processes for their preparation and their use in medicaments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399291A2 (en) * 1989-05-23 1990-11-28 Bayer Ag Substituted (Quinoline-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides , process for their preparation and their use in medicines
EP0480708A2 (en) * 1990-10-12 1992-04-15 Merck Frosst Canada Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
EP0582908A1 (en) * 1992-08-11 1994-02-16 Bayer Ag 2-Substituted guinolylmethoxy-phenylacetic acid derivatives, process for their preparation and their pharmaceutical use
EP0593976A1 (en) * 1992-10-19 1994-04-27 Bayer Ag Crystalline (R)-(-)-2-cycloheptyl-N-methylsulfonyl-4-(2-quinolinyl-methoxy)-phenyl-acetamide

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARA G ET AL: "CYCLOOXYGENASE AND LIPOXYGENASE INHIBITORS IN CANCER THERAPY", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 54, 1996, pages 3 - 16, XP002053643, ISSN: 0952-3278 *
HATZELMANN A ET AL: "MODE OF ACTION OF THE LEUKOTRIENE SYNTHESIS (FLAP) INHIBITOR BAY X 1005: IMPLICATIONS FOR BIOLOGICAL REGULATION OF 5-LIPOXYGENASE", AGENTS AND ACTIONS, BIRKHAEUSER VERLAG, BASEL, CH, vol. 43, no. 1/2, November 1994 (1994-11-01), pages 64 - 68, XP000984599, ISSN: 0065-4299 *
MUELLER-PEDDINGHAUS R ET AL: "BAY X1005, A NEW SELECTIVE INHIBITOR OF LEUKOTRIENE SYNTHESIS: PHARMACOLOGY AND PHARMACOKINETICS", JOURNAL OF LIPID MEDIATORS, AMSTERDAM, NL, vol. 6, no. 1-3, March 1993 (1993-03-01), pages 245 - 248, XP000984668, ISSN: 0921-8319 *
MUNGER K A ET AL: "BENEFICIAL EFFECTS OF 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITION IN ACCELERATED NEPHROTOXIC SERUM NEPHRITIS (AGN) AND PASSIVE HEYMANN'S NEPHRITIS (PHN) IN RATS", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 10, 1 November 1999 (1999-11-01), pages 533A, XP000984671, ISSN: 1046-6673 *
STEELE V E ET AL: "LIPOXYGENASE INHIBITORS AS POTENTIAL CANCER CHEMOPREVENTIVES", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH,, US, vol. 8, no. 5, May 1999 (1999-05-01), pages 467 - 483, XP000984604, ISSN: 1055-9965 *
STEELE V E ET AL: "POTENTIAL USE OF LIPOXYGENASE INHIBITORS FOR CANCER CHEMOPREVENTION", CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 9, no. 9, 2000, pages 2121 - 2138, XP000984611, ISSN: 0967-8298 *

Also Published As

Publication number Publication date
GB2356139A (en) 2001-05-16
WO2001035936A2 (en) 2001-05-25
GB9926985D0 (en) 2000-01-12
AU2354301A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
SG151249A1 (en) 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2004018451A8 (en) Pyridazinone-derivatives as pde4 inhibitors
CA2288705A1 (en) Use of quinazoline compounds for the treatment of polycystic kidney disease
MXPA03010961A (en) Thiazole compounds useful as inhibitors of protein kinases.
BG105270A (en) Tetrahydropyridoethers
WO2002087513A3 (en) Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
WO1999054326A8 (en) Dihydropyrimidines
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
MA27561A1 (en) AMINOINDAZOLES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
BG106586A (en) Pyrazolopyramidines as therapeutic agents
WO2002032874A8 (en) Substituted heterocyclic compounds for treating multidrug resistance
SG151250A1 (en) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2004106293A3 (en) Oxazolyl - and thiazolyl - purine based tricyclic compounds.
WO2004080422A3 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2002094020A8 (en) Use of triazolopyrimidine derivatives as microbicides in the protection of materials
WO2005046672A3 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
AU1044500A (en) Imidazonaphthyridines
WO2001072754A8 (en) Alkylated imidazopyridine derivatives
WO2000037464A3 (en) 4-(aminoalkoxy)benzofurans as n-myristoyltransferase inhibitors
MXPA02009551A (en) Prodrugs of imidazopyridine derivatives.
WO1999012933A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
HK1067365A1 (en) Tetrahydropyrido compounds
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2004075846A3 (en) Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase